$VTGN News

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss

Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol Did Not Achieve Its Primary Endpoint

Vistagen Therapeutics (NASDAQ:VTGN) Faces Muted Market Sentiment as Crucial PALISADE-4 Data Looms

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?

Vistagen Announces Its Data From PALISADE-3 Phase 3 Trial Of Fasedienol Demonstrates Well-Toleration, No Drug-Related Safety Concerns

Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2

Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary

Vistagen Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

Vistagen Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ...

Vistagen Therapeutics Inc (NASDAQ:VTGN) Reports Mixed Q3 Results Amid Key Clinical Trial Updates

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates